What is bremelanotide, its recommended dosing, contraindications, and side effects for treating acquired hypoactive sexual desire disorder in premenopausal women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Bremelanotide for Hypoactive Sexual Desire Disorder

Bremelanotide (Vyleesi) is an FDA-approved melanocortin receptor agonist specifically indicated for treating acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as a 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity. 1

What is Bremelanotide

Bremelanotide is a synthetic peptide analogue of alpha-melanocyte stimulating hormone (α-MSH) with high affinity for the melanocortin type 4 receptor, which modulates brain pathways involved in sexual response 2. It works centrally to enhance sexual desire and reduce distress related to low libido.

Specific Indication

The drug is indicated only for premenopausal women with acquired, generalized HSDD where low sexual desire causes marked distress or interpersonal difficulty and is NOT due to 1:

  • A co-existing medical or psychiatric condition
  • Relationship problems
  • Effects of medication or drug substances

"Acquired" means the disorder developed in someone who previously had normal sexual desire. "Generalized" means it occurs regardless of stimulation type, situation, or partner. 1

Recommended Dosing

Administer 1.75 mg subcutaneously to the abdomen or thigh at least 45 minutes before anticipated sexual activity 1. The drug comes as a prefilled autoinjector pen containing 1.75 mg/0.3 mL solution 1.

Critical Dosing Restrictions:

  • Never exceed one dose within 24 hours (consecutive doses may cause additive blood pressure effects) 1
  • Maximum 8 doses per month recommended (more frequent dosing increases hyperpigmentation risk and prolonged blood pressure elevation) 1
  • Discontinue after 8 weeks if no symptom improvement 1

The optimal timing window is not fully characterized; patients should determine their best administration time based on duration of effect and tolerability, particularly nausea 1.

Contraindications

Absolute contraindications 1:

  • Uncontrolled hypertension
  • Known cardiovascular disease

Warnings and Precautions

Blood Pressure and Heart Rate Changes

Bremelanotide transiently increases blood pressure (maximal increases: 6 mmHg systolic, 3 mmHg diastolic) and decreases heart rate (up to 5 bpm) peaking 2-4 hours post-dose, usually resolving within 12 hours 1. Assess cardiovascular risk before initiating treatment and ensure blood pressure is well-controlled. The drug is not recommended in patients at high cardiovascular risk. 1

Focal Hyperpigmentation

Reported in 1% of patients receiving up to 8 doses monthly, affecting face, gingiva, and breasts 1. Risk is higher in patients with darker skin and with daily dosing. Resolution was not confirmed in some patients—consider discontinuation if hyperpigmentation develops. 1

Nausea

The most significant tolerability issue: 40% of patients experience nausea, with 13% requiring anti-emetic therapy and 8% discontinuing treatment 1. Nausea typically improves with the second dose 1. Consider discontinuing or initiating anti-emetic therapy for persistent or severe nausea 1.

Common Side Effects

Side effects occurring in >4% of patients 1:

  • Nausea (40%)—most common, usually improves after first dose
  • Flushing (20%)
  • Injection site reactions
  • Headache (11%)
  • Vomiting

Most adverse events are mild to moderate in intensity and related to tolerability 3.

Drug Interactions

  • Bremelanotide may slow gastric emptying, potentially affecting absorption of concomitantly administered oral medications 1
  • Significantly decreases systemic exposure of oral naltrexone—avoid use with oral naltrexone-containing products for alcohol or opioid addiction 1

Special Populations

  • Pregnancy: Discontinue if pregnancy is suspected 1
  • Females of reproductive potential: Use effective contraception while taking bremelanotide 1
  • Not indicated for postmenopausal women or men 1
  • Not indicated to enhance sexual performance 1

Clinical Efficacy

Two identical Phase 3 trials (RECONNECT studies) demonstrated statistically significant improvements compared to placebo 3:

  • Sexual desire (FSFI-desire domain): Integrated improvement of 0.35 (p<0.001)
  • Distress related to low desire (FSDS-DAO item 13): Integrated reduction of -0.33 (p<0.001)

A recent 2026 meta-analysis confirmed bremelanotide improves total FSFI scores and both desire and arousal subscales 4.

Clinical Context from Guidelines

While ASCO guidelines mention flibanserin for premenopausal women with HSDD, they note it has not been evaluated in women with cancer history or on endocrine therapy, with uncertain risk/benefit ratio 5. Bremelanotide represents an alternative on-demand option versus daily flibanserin, though guidelines predate its approval.

The key clinical advantage is on-demand dosing rather than daily administration, but this comes with the trade-off of injection-related side effects and the significant nausea burden that affects 40% of users.

References

Related Questions

What is the recommended dosing regimen, contraindications, and monitoring requirements for bremelanotide (used to treat acquired generalized hypoactive sexual desire disorder in premenopausal adults)?
How do bremelanotide and flibanserin affect sexual desire in premenopausal women with hypoactive sexual desire disorder, and what outcome measures (Female Sexual Function Index desire domain, Female Sexual Distress Scale, and number of satisfying sexual events) are used to assess their efficacy?
What is the recommended protocol for subcutaneous bremelanotide administration in a premenopausal adult woman with hypoactive sexual desire disorder, including eligibility criteria, dosing, injection technique, site rotation, monitoring, and contraindications?
In a premenopausal woman with acquired generalized hypoactive sexual desire disorder, can buspirone (a 5‑HT1A partial agonist) be used as a first‑line or approved therapy?
What are the indications, dosing regimen, contraindications, adverse effects, and counseling considerations for flibanserin in premenopausal women with acquired generalized hypoactive sexual desire disorder?
How should persistent leukopenia be managed in patients with multiple myeloma after autologous stem cell transplantation?
In a 12‑year‑old girl (~53 kg), what laboratory and clinical criteria distinguish mild from moderate hyperthyroidism?
What is the appropriate treatment for a 12-year-old girl weighing 53 kg with a free T4 of 2.10 ng/dL (mild hyperthyroidism)?
What are the indications, dosing regimen, contraindications, adverse effects, and counseling considerations for flibanserin in premenopausal women with acquired generalized hypoactive sexual desire disorder?
What are the optimal nutrition and supplement recommendations for weight loss in a generally healthy menopausal woman?
Given an anion gap of 21 mEq/L, a bicarbonate of 19 mEq/L, and a ketone level of 1.56 mmol/L, does this indicate diabetic ketoacidosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.